Your results have been filtered for all content within all Money Map Press subscriptions

On Friday, the Dow Jones snapped its longest streak of record highs since 1987.

Stocks are hovering near record-territory and we're riding the upside of incredible optimism about the U.S. economy and the Trump administration. Earlier this week, we warned that investors could start to get wary about the rally if it becomes more apparent that Trump's White House will not be able to get its economic policies passed in the next few months.

 
Your current subscriptions do not allow access to this search result.
Learn More

As a Passport Fellowship member, you're already aware of the money-making potential of recommendations in Money Map Report, Energy Advantage, and Nova-X Report

It's no secret that Keith, Kent, and Michael are absolutely crushing this rally.

In Money Map Report, Keith's open portfolio is up 42.22% across all open stock positions. Kent's Energy Advantage recommendations are up 38.47%. And Michael's Nova-X Report portfolio is up 22.02%.

But that's just the tip of the iceberg...

 
Your current subscriptions do not allow access to this search result.
Learn More

This is a rough climate for short sellers, to put it mildly.

In my hedge fund, as well as in Zenith Trading Circle, we are experiencing some pain right now as a number of our short plays continue to rise despite miserable fundamentals, mounds of debt, ridiculous overvaluation, misleading reporting, and terrible products. (In some cases, even though the underlying stocks have started to fall after bad news or earnings, the options still remain obstinately in the red.) Every time I look at these plays, I feel sick to my stomach.

 
Your current subscriptions do not allow access to this search result.
Learn More

The Energy Advantage Portfolio security plays continue to grow quickly, as tensions in Asia especially keep rising.

With North Korea's missile tests and likely assassination of their dictator's brother in Malaysia, as well as China's continued push for control over the whole of the South China Sea...

America absolutely needs to be ready for anything.

 
Your current subscriptions do not allow access to this search result.
Learn More

It's only been a week, and already Evolution Petroleum Corp. (EPM), one of our American Superstar Trades, is up more than 8%.

Evolution's operations in Louisiana are in a class of their own. Their patented technology - called "Artificial Lift" - extends the life and production of both oil and gas wells. In other words, they get more product out of every well they drill.

 
Your current subscriptions do not allow access to this search result.
Learn More

While the legal cannabis industry and its investors have wondered if and what level of pushback would come from President Donald Trump and new U.S. Attorney General Jeff Sessions, a group of federal lawmakers have mobilized to defend marijuana's snowballing momentum.

In order to do so, Reps. Earl Blumenauer (D-Ore.), Jared Polis (D-Colo.), Dana Rohrabacher (R-Calif.), and Don Young (R-Alaska) have launched the Congressional Cannabis Caucus.

Playing on the strength of marijuana initiatives at the ballot box on Election Day, the bipartisan quartet in the House of Representatives decided not to wait out demographic changes, slowly fading opposition from older lawmakers, or any potential problem initiatives that could arise from the Trump administration.

 
Your current subscriptions do not allow access to this search result.
Learn More

Sometimes, everyone's bullish and the charts say "Not so fast!"

This is when you have to take a good, hard look and see if there's a smart way to make a contrarian play.

That exact setup is staring us in the face today with crude oil.

 
Your current subscriptions do not allow access to this search result.
Learn More

As you know, we took another double on AAPL yesterday. We also took our URI calls off the book.

And now, here's a look at how the rest of our open positions are doing...

 
Your current subscriptions do not allow access to this search result.
Learn More

Earlier this week, as you know, shares of Trevena Inc. (NasdaqGS:TRVN) fell precipitously after the company released positive data from two phase-3 studies of its painkilling drug Olinvo (oliceridine).

It's unusual for the market to react in this way to good news in biotech, but it does occasionally happen, particularly when interpretation of results requires investors to make judgments outside of their usual parameters.

Here's what happened. (This gets just a little technical, but bear with me.)

 
Your current subscriptions do not allow access to this search result.
Learn More